(Tradingsat.com) – NicOx announced Thursday morning the signing of an agreement with U.S. pharmaceutical company Pfizer to reacquire all rights to development and commercialization of PF-03187207, NicOx compound developed for the treatment of patients with open-angle glaucoma and ocular hypertension…

We believe that the PF-03187207 has good potential to be recorded for glaucoma and ocular hypertension. We will evaluate opportunities for the advancement of PF-03187207 in Phase 3, including possible partnerships with third parties. Says Gavin Spencer, Vice President of Business Development at NicOx.

This agreement demonstrates our ongoing commitment to license and permit our business partners to reacquire the programs of R D are no longer part of our core strategy but may become important drugs for patients and physicians., For its part says David K. Rosen, Head of Licensing Out of Pfizer.

For the record, following the results of two Phase 2 trials, Pfizer had decided in 2008 not to launch Phase 3 program for PF-03187207. These studies in the United States and Japan aimed to compare the safety and efficacy of several doses of PF 03187207 to Xalatan ?®, a patented product by Pfizer, seeded in global sales for the treatment glaucoma.

It is also anticipated that NicOx access to information for development of Xalatan ?® owned by Pfizer and can use, and refer to regulatory filings Xalatan ?®, which could be important for potential future development and regulatory submission of PF-03187207, said the biotech company.



.